Paratek Pharmaceuticals Price To Sales vs. Total Debt

PRTKDelisted Stock  USD 2.18  0.00  0.00%   
Based on Paratek Pharmaceuticals' profitability indicators, Paratek Pharmaceuticals may not be well positioned to generate adequate gross income at the moment. It has a very high risk of underperforming in January. Profitability indicators assess Paratek Pharmaceuticals' ability to earn profits and add value for shareholders.
For Paratek Pharmaceuticals profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Paratek Pharmaceuticals to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Paratek Pharmaceuticals utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Paratek Pharmaceuticals's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Paratek Pharmaceuticals over time as well as its relative position and ranking within its peers.
  
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
Please note, there is a significant difference between Paratek Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Paratek Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Paratek Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Paratek Pharmaceuticals Total Debt vs. Price To Sales Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Paratek Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Paratek Pharmaceuticals value to that of its competitors to determine the firm's financial worth.
Paratek Pharmaceuticals is rated below average in price to sales category among its peers. It is rated top company in total debt category among its peers making up about  301,956,064  of Total Debt per Price To Sales. Comparative valuation analysis is a catch-all technique that is used if you cannot value Paratek Pharmaceuticals by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

Paratek Total Debt vs. Price To Sales

Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.

Paratek Pharmaceuticals

P/S

 = 

MV Per Share

Revenue Per Share

 = 
0.86 X
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.
Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.

Paratek Pharmaceuticals

Total Debt

 = 

Bonds

+

Notes

 = 
258.41 M
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.

Paratek Total Debt vs Competition

Paratek Pharmaceuticals is rated top company in total debt category among its peers. Total debt of Health Care industry is at this time estimated at about 357.43 Million. Paratek Pharmaceuticals totals roughly 258.41 Million in total debt claiming about 72% of equities under Health Care industry.
Total debt  Valuation  Workforce  Revenue  Capitalization

Paratek Pharmaceuticals Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Paratek Pharmaceuticals, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Paratek Pharmaceuticals will eventually generate negative long term returns. The profitability progress is the general direction of Paratek Pharmaceuticals' change in net profit over the period of time. It can combine multiple indicators of Paratek Pharmaceuticals, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Paratek Pharmaceuticals, Inc. was founded in 1996 and is headquartered in Boston, Massachusetts. Paratek Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 207 people.

Paratek Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Paratek Pharmaceuticals. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Paratek Pharmaceuticals position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Paratek Pharmaceuticals' important profitability drivers and their relationship over time.

Learn to be your own money manager

Our tools can tell you how much better you can do entering a position in Paratek Pharmaceuticals without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Money Managers Now

   

Money Managers

Screen money managers from public funds and ETFs managed around the world
All  Next Launch Module

Use Investing Themes to Complement your Paratek Pharmaceuticals position

In addition to having Paratek Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Russia On Wall Street Thematic Idea Now

Russia On Wall Street
Russia On Wall Street Theme
Cross-sector and cross-instrument bundle of publicly traded Russian entities that are expected to be listed on USA exchanges or over the counter. The Russia On Wall Street theme has 23 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Russia On Wall Street Theme or any other thematic opportunities.
View All  Next Launch
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.

Other Consideration for investing in Paratek Stock

If you are still planning to invest in Paratek Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Paratek Pharmaceuticals' history and understand the potential risks before investing.
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Bonds Directory
Find actively traded corporate debentures issued by US companies
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm